查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018598

肝病診斷市場：按產品、疾病和最終用戶分類－2026-2032年全球市場預測

Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肝病診斷市值將達到 146 億美元，到 2026 年將成長至 158.9 億美元，到 2032 年將達到 275.7 億美元，複合年成長率為 9.51%。

主要市場統計數據
基準年 2025 146億美元
預計年份：2026年 158.9億美元
預測年份 2032 275.7億美元
複合年成長率 (%) 9.51%

全面概述不斷變化的診斷格局，其中臨床緊迫性、創新和政策正在重塑肝病檢測和治療的途徑。

我們首先說明快速發展的診斷生態系統，在這個生態系統中，技術創新、臨床需求和監管變革相互交織，重新定義了我們檢測、分期和監測肝臟疾病的方式。非侵入性檢測技術的進步、影像解析度的提高以及更靈敏的血液標記物的出現，正在重塑臨床路徑，而醫療系統也在尋求能夠縮短診斷時間並支持以價值為導向的醫療模式的診斷方法。因此，臨床、商業和政策領域的相關人員必須重新審視傳統方法，並考慮採用與現代醫療模式相契合的綜合診斷演算法。

技術創新、臨床重點以及不斷變化的監管和報銷壓力如何共同改變肝病診斷的交付模式。

技術、臨床和商業性等多個方面的變革正在重塑肝病診斷格局。在技​​術層面，診斷方法正朝著微創或非侵入性方向發展，力求在診斷準確性和患者舒適度之間取得平衡。這包括先進的影像技術、增強的檢查室生物標記檢測以及從現有數據流中提取新訊號的計算分析。在臨床層面，重點正從孤立的診斷轉向疾病的長期監測，從而實現早期療育和更精細的風險分層。

預測和管理 2025 年關稅調整對診斷設備和試劑的採購、供應鏈和部署計劃的連鎖反應。

關稅等政策措施可能會為全球診斷價值鏈帶來新的複雜性，尤其對於在生產和分銷過程中跨境運輸的零件和設備而言更是如此。在美國，已宣布將於2025年實施的關稅調整可能會影響診斷設備、成像設備和專用試劑的採購，迫使製造商重新評估其籌資策略，並促使醫療服務提供者評估總體擁有成本。這些調整可能會加速供應商整合，促進供應鏈本地化，並促使製造商與醫療系統談判長期契約，以穩定需求和價格。

基於細分的詳細洞察，將產品類型、特異性疾病的診斷需求和最終用戶工作流程連結起來，從而指導產品和臨床策略。

市場區隔揭示了診斷技術創新集中在哪些領域，以及臨床工作流程如何與產品功能相互作用。以檢測方式分析市場，切片檢查技術仍然是組織學確診的基礎，其中腹腔鏡肝臟切片檢查、經皮肝切片檢查和經靜脈肝切片檢查分別針對不同的臨床場景，滿足不同的安全性要求和檢體收集需求。同時，血液學檢測也在不斷發展，不再局限於基礎肝功能檢查。雖然以丙氨酸胺基轉移酶(ALT)、天冬氨酸胺基轉移酶(AST) 和γ-谷氨醯轉移酶 (GGT) 為中心的檢測仍然是常規項目，但多重檢測和新型生物標記正在湧現，以提高檢測的特異性和長期監測能力。診斷影像技術，包括電腦斷層掃描、MRI和超音波，也在不斷發展，解析度不斷提高，功能性影像定序和軟體主導的定量分析能夠更好地輔助臨床醫生的解讀。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和不同的引進模式會影響戰略市場進入和業務擴張決策。

區域趨勢影響肝病診斷的需求和創新路徑，美洲、歐洲、中東和非洲以及亞太地區的情況各不相同。在美洲，臨床實踐強調擴充性和與大規模醫療保健系統的整合，強大的腫瘤學和肝病學研究網路推動了先進影像學和分子檢測技術的早期應用。該地區的醫療保健系統也傾向於優先考慮能夠評估臨床和經濟價值的報銷模式，這影響著新診斷方法的定位和實施。

設備製造商、測試方法開發商、測試網路和敏捷型Start-Ups之間的競爭和策略合作將塑造該行業的未來。

肝病診斷領域的企業格局呈現出多元化的格局，既包括成熟的儀器製造商，也包括專業的檢測研發公司、臨床實驗室網路以及專注於利基生物標記創新的敏捷型Start-Ups。現有的影像和儀器供應商繼續利用其現有的儀器基礎設施和服務關係，並實施軟體驅動的改進。同時，專業的檢測研發公司正致力於進行臨床檢驗試驗，並獲得主要監管機構的核准，將產品從研究用途推向臨床應用。臨床實驗室運營商則優先考慮標準化、處理能力以及與電子健康記錄的整合，並透過常規的篩檢和監測方案來確保檢測量。

為診斷開發公司和醫療產業領導者提供實用策略指南，以加速臨床部署、最佳化供應彈性並確保報銷一致性。

行業領先企業若想在肝病診斷領域維持並擴大市場佔有率，必須將商業策略與臨床證據的累積和切實可行的推廣計劃相結合。優先進行嚴謹的前瞻性研究，以驗證其在真實臨床環境中的效用，有助於加強醫保報銷談判，並提升臨床醫師的信心。同時，透過無縫整合電子健康記錄 (EHR)、採用標準化報告格式和決策支援演算法，將診斷結果整合到治療路徑中，可以減少臨床工作流程中的摩擦，並促進診斷結果的採納。

我們高度透明、專家主導的調查方法，結合了相關人員訪談、與臨床指南的一致性以及交叉檢驗證據的整合，為實際結論提供了支持。

本調查方法融合了定性和定量方法，以確保研究結果的穩健性、可重複性和臨床意義。主要資料收集包括對臨床醫生、檢查室管理人員和行業高管進行結構化訪談，以了解實踐模式、未滿足的需求以及推廣應用的障礙。專家意見與同行評審文獻、監管文件和臨床指南等二級資訊來源進行交叉比對，以檢驗臨床結論，並在標準診療框架內解讀新興技術。

整合策略挑戰，展現主導創新、整合工作流程和彈性營運結構將如何決定肝病診斷領域未來的領導地位。

總之，這項分析指出，肝病診斷領域正處於一個轉捩點，技術進步、臨床對微創檢測的需求以及醫保報銷政策的轉變，都創造了重要的策略機會。能夠展現清晰的臨床效用、無縫融入醫療服務提供者的工作流程並有效管理供應鏈和政策風險的公司，將佔據主導地位。同時，採取務實方法進行檢驗和整合的醫療系統和檢查室，也將受益於更最佳化的患者照護路徑和更高的營運效率。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肝病診斷市場：依產品/服務分類

  • 切片檢查方法
    • 腹腔鏡肝臟切片檢查
    • 經皮肝穿刺切片檢查
    • 經靜脈肝切片檢查
  • 驗血
    • 丙氨酸胺基轉移酶試驗
    • 天門冬胺酸胺基轉移酶試驗
    • γ-谷氨醯轉肽酶試驗
  • 內視鏡檢查
  • 診斷影像
    • 電腦斷層掃描
    • MRI
    • 超音波檢查

第9章 肝病診斷市場：依疾病類型分類

  • 急性肝炎
  • 酒精性肝臟疾病
  • 慢性肝炎
  • 肝硬化
  • 肝細胞癌
  • 非酒精性脂肪肝疾病

第10章 肝病診斷市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 研究機構

第11章 肝病診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 肝病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 肝病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國肝病診斷市場

第15章：中國肝病診斷市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Amgen Inc.
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Boston Scientific Corporation
  • Cook Medical Incorporated
  • Echosens by Astor Partners Srl
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hepatiq, Inc.
  • Hologic, Inc.
  • Horiba, Ltd.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Medtronic PLC
  • Merck & Co., Inc.
  • Perspectum Ltd.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Ri.Mos. Srl
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-B9334AD6C587

The Liver Disease Diagnostics Market was valued at USD 14.60 billion in 2025 and is projected to grow to USD 15.89 billion in 2026, with a CAGR of 9.51%, reaching USD 27.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.60 billion
Estimated Year [2026] USD 15.89 billion
Forecast Year [2032] USD 27.57 billion
CAGR (%) 9.51%

A comprehensive orientation to the evolving diagnostic landscape where clinical urgency, innovation, and policy are reshaping liver disease detection and care pathways

The opening section situates the reader in a rapidly evolving diagnostic ecosystem where technological innovation, clinical need, and regulatory change are converging to redefine how liver disease is detected, staged, and monitored. Advances in non-invasive testing, improvements in imaging resolution, and more sensitive blood-based markers are reshaping clinical pathways, while health systems seek diagnostics that reduce time-to-diagnosis and support value-based care. As a result, stakeholders across clinical, commercial, and policy domains must reassess legacy approaches and consider integrated diagnostic algorithms that align with contemporary care models.

This introduction frames the broader narrative by outlining the central forces driving change: clinician demand for actionable information, patient preference for less invasive options, and payer emphasis on care efficiency and outcomes. It highlights the interplay between traditional histopathology and emerging modalities, and sets expectations for the analysis that follows by underscoring the need for strategic planning, cross-disciplinary collaboration, and investment in evidence generation to accelerate adoption and optimize clinical utility.

How technological innovation, clinical priorities, and evolving regulatory and reimbursement pressures are jointly transforming liver disease diagnostics delivery models

Several transformative shifts are redefining the liver disease diagnostics landscape, spanning technological, clinical, and commercial dimensions. On the technological front, there is a pronounced move toward minimally invasive or non-invasive modalities that balance diagnostic accuracy with patient comfort, including refined imaging, enhanced lab-based biomarkers, and computational analytics that extract new signal from established data streams. Clinically, the emphasis is shifting from episodic diagnosis to longitudinal disease monitoring, enabling earlier intervention and more nuanced risk stratification.

From a commercial perspective, partnerships between diagnostic developers, imaging vendors, and laboratory services are becoming more strategic, aimed at delivering integrated solutions rather than point products. Regulatory frameworks are evolving to accommodate novel diagnostics, and payers are increasingly focused on evidence of clinical utility and cost-effectiveness to inform reimbursement decisions. Taken together, these shifts favor companies that can demonstrate robust clinical validation, seamless integration into care pathways, and clear value propositions for providers and payers.

Anticipating and managing the ripple effects of 2025 tariff adjustments on procurement, supply chains, and adoption timelines for diagnostic devices and reagents

Policy actions like tariffs can introduce new complexities into the global diagnostics value chain, particularly for components and instruments that travel across borders during manufacturing and distribution. In the United States, tariff changes announced in 2025 have the potential to influence procurement economics for diagnostic equipment, imaging hardware, and specialized reagents, creating pressure on manufacturers to reassess sourcing strategies and on providers to evaluate total cost of ownership. These adjustments may accelerate supplier consolidation, regionalize supply chains, and prompt manufacturers to negotiate long-term contracts with health systems to stabilize demand and pricing.

Beyond procurement, tariffs can affect investment timing for new product introductions, as companies weigh the commercial viability of launches in markets with altered import dynamics. Service providers and diagnostic laboratories may respond by intensifying local manufacturing partnerships or increasing inventory buffers to manage short-term pricing volatility. In addition, the ripple effects can influence clinical adoption rates where capital-intensive imaging upgrades are deferred, thereby shaping the pace at which advanced modalities diffuse into routine practice. Strategic responses that combine supply-chain diversification, contractual hedging, and value demonstration to payers will be critical to mitigating the cumulative impact of tariff-related disruption.

Deep segmentation-driven insights that connect offering types, disease-specific diagnostic needs, and end-user workflows to guide product and clinical strategy

Segmentation illuminates where diagnostic innovation is concentrated and how clinical workflows interact with product capabilities. When the market is parsed by offering, biopsy techniques remain foundational for definitive tissue diagnosis, with laparoscopic liver biopsy, percutaneous liver biopsy, and transvenous liver biopsy each serving distinct clinical scenarios tied to safety profile and sampling needs. Concurrently, blood-based tests are advancing beyond basic hepatic panels: assays centered on alanine transaminase, aspartate transaminase, and gamma-glutamyl transpeptidase continue to be routine, while multiplexed and novel biomarkers are emerging to improve specificity and longitudinal monitoring. Imaging diagnostics-spanning CT scan, MRI, and ultrasound-are evolving through enhanced resolution, functional imaging sequences, and software-driven quantification that augment clinician interpretation.

Disease-type segmentation further clarifies demand patterns and clinical imperatives across acute hepatitis, alcoholic liver disease, chronic hepatitis, cirrhosis, hepatocellular carcinoma, and non-alcoholic fatty liver disease, each driving distinct testing strategies and follow-up regimens. End-user segmentation identifies where innovation is operationalized: diagnostic laboratories optimize high-throughput analytics and assay validation; hospitals integrate multimodal diagnostics into patient pathways and procedural workflows; and research institutes advance biomarker discovery and clinical validation. Together, these lenses provide a granular view of clinical need, technology fit, and deployment contexts that should guide product development and commercialization strategies.

Regional dynamics and differentiated adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape strategic market entry and scale-up decisions

Regional dynamics shape both demand and innovation pathways in liver disease diagnostics, with distinct considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical practice emphasizes scalability and integration of diagnostics into large health systems, with strong oncology and hepatology research networks driving early adoption of advanced imaging and molecular assays. Health systems in this region also tend to prioritize reimbursement models that reward demonstrable clinical and economic value, influencing how new diagnostics are positioned and adopted.

The Europe, Middle East & Africa region exhibits heterogeneity in regulatory environments and healthcare infrastructure, which creates a patchwork of adoption rates and market access strategies. Countries with centralized health technology assessment processes demand robust clinical evidence, while others exhibit faster uptake for pragmatic, cost-effective solutions. In Asia-Pacific, rapid investment in diagnostic capacity, growing burden of non-alcoholic fatty liver disease, and expanding diagnostic manufacturing capabilities are catalyzing both domestic innovation and export-oriented production. Across all regions, cross-border collaboration, regulatory harmonization, and attention to localized clinical workflows remain essential for successful product introduction and scale-up.

Competitive behaviors and strategic partnerships among instrument makers, assay innovators, laboratory networks, and nimble startups that are defining industry trajectories

Company behavior in the liver disease diagnostics space is being shaped by a mix of established instrument manufacturers, specialized assay developers, clinical laboratory networks, and nimble start-ups focused on niche biomarker innovations. Incumbent imaging and instrument providers continue to leverage installed bases and service relationships to introduce software-enabled enhancements, while specialized assay developers pursue clinical validation studies and key regulatory clearances to move from research use to clinical adoption. Clinical laboratory operators emphasize standardization, throughput, and integration with electronic medical records to capture volume from routine screening and monitoring protocols.

Collaborative models are increasingly prevalent, with partnerships and co-development agreements linking assay innovators to lab networks or imaging vendors to create combined diagnostic offerings. Strategic alliances that align clinical validation efforts with payer engagement accelerate reimbursement conversations and practical adoption. Meanwhile, smaller companies often pursue targeted clinical niches-such as non-invasive fibrosis assessment or early tumor detection-to establish clinical utility before broadening their commercial footprint. Manufacturers that prioritize interoperability, rigorous evidence generation, and scalable manufacturing will be best positioned to sustain growth amid competitive and regulatory pressures.

Actionable strategic playbook for diagnostic developers and healthcare leaders to accelerate clinical adoption, optimize supply resilience, and secure reimbursement alignment

Industry leaders seeking to maintain or grow their presence in liver disease diagnostics should align commercial strategy with clinical evidence generation and pragmatic deployment plans. Prioritizing rigorous prospective studies that demonstrate clinical utility in real-world settings will strengthen reimbursement discussions and clinician confidence. At the same time, integrating diagnostic outputs into care pathways-through seamless electronic health record connectivity, standardized reporting formats, and decision-support algorithms-will increase adoption by reducing friction in clinical workflows.

From an operational perspective, diversifying supply chains, pursuing regional manufacturing partnerships, and cultivating long-term procurement agreements can mitigate exposure to tariff-induced volatility. Commercial teams should also develop tiered market entry plans that account for regional regulatory variance and payer landscapes, leveraging pilot deployments and local opinion leaders to build momentum. Finally, cultivating collaborative relationships with hospitals, diagnostic laboratories, and research institutions enables iterative product refinement and supports the evidence generation needed to sustain broad clinical uptake.

A transparent, expert-driven methodology combining stakeholder interviews, clinical guideline alignment, and cross-validated evidence synthesis to underpin actionable conclusions

The research methodology integrates qualitative and quantitative approaches to ensure findings are robust, reproducible, and clinically relevant. Primary data collection includes structured interviews with clinicians, laboratory directors, and industry executives to capture practice patterns, unmet needs, and adoption barriers. Expert advisory input is triangulated with secondary sources, including peer-reviewed literature, regulatory filings, and clinical guidelines, to validate clinical claims and interpret emerging technologies within standard-of-care frameworks.

Analytical procedures emphasize cross-validation across multiple information streams, with evidence synthesis focused on clinical utility, integration feasibility, and commercialization readiness. Segmentation mapping aligns offerings, disease types, and end-user contexts to reflect real-world deployment scenarios. Quality assurance processes include expert review cycles and methodological documentation that transparently describe inclusion criteria, data sources, and assumptions. Limitations are acknowledged, particularly where nascent technologies lack long-term outcome data, and recommendations are framed to reflect the current evidence base while identifying areas where further validation is needed.

Synthesis of strategic imperatives showing how evidence-driven innovation, integrated workflows, and resilient operations will determine future leadership in liver disease diagnostics

This analysis concludes that the liver disease diagnostics landscape is at an inflection point where technological progress, clinical demand for less invasive testing, and shifting reimbursement priorities converge to create significant strategic opportunities. Companies that can demonstrate clear clinical utility, integrate seamlessly into provider workflows, and manage supply-chain and policy risks will be positioned to lead. At the same time, health systems and laboratories that adopt a pragmatic approach to validation and integration will realize benefits in patient care pathways and operational efficiency.

Looking forward, the most transformative gains will arise from diagnostic solutions that enable earlier detection, more precise disease staging, and longitudinal monitoring that informs treatment choices. Realizing this potential requires sustained investment in clinical evidence, collaborative commercialization models, and adaptive operational strategies that respond to regional and policy dynamics. Stakeholders who embrace cross-sector partnerships and prioritize patient-centered outcomes will be best placed to translate diagnostic innovation into improved clinical practice and health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Disease Diagnostics Market, by Offering

  • 8.1. Biopsy Techniques
    • 8.1.1. Laparoscopic Liver Biopsy
    • 8.1.2. Percutaneous Liver Biopsy
    • 8.1.3. Transvenous Liver Biopsy
  • 8.2. Blood-Based Tests
    • 8.2.1. Alanine Transaminase Test
    • 8.2.2. Aspartate Transaminase Test
    • 8.2.3. Gamma-Glutamyl Transpeptidase Test
  • 8.3. Endoscopy
  • 8.4. Imaging Diagnostics
    • 8.4.1. CT Scan
    • 8.4.2. MRI
    • 8.4.3. Ultrasound

9. Liver Disease Diagnostics Market, by Disease Type

  • 9.1. Acute Hepatitis
  • 9.2. Alcoholic Liver Disease
  • 9.3. Chronic Hepatitis
  • 9.4. Cirrhosis
  • 9.5. Hepatocellular Carcinoma
  • 9.6. Non-Alcoholic Fatty Liver Disease

10. Liver Disease Diagnostics Market, by End-User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Liver Disease Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Liver Disease Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Liver Disease Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Liver Disease Diagnostics Market

15. China Liver Disease Diagnostics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Amgen Inc.
  • 16.7. Argon Medical Devices, Inc.
  • 16.8. Bayer AG
  • 16.9. Becton, Dickinson and Company
  • 16.10. Bio-Rad Laboratories, Inc.
  • 16.11. BioMerieux SA
  • 16.12. Boston Scientific Corporation
  • 16.13. Cook Medical Incorporated
  • 16.14. Echosens by Astor Partners S.r.l.
  • 16.15. Epigenomics AG
  • 16.16. F. Hoffmann-La Roche Ltd.
  • 16.17. Fujifilm Holdings Corporation
  • 16.18. Hepatiq, Inc.
  • 16.19. Hologic, Inc.
  • 16.20. Horiba, Ltd.
  • 16.21. Koninklijke Philips N.V.
  • 16.22. Laboratory Corporation of America Holdings
  • 16.23. Medtronic PLC
  • 16.24. Merck & Co., Inc.
  • 16.25. Perspectum Ltd.
  • 16.26. Qiagen N.V.
  • 16.27. Quest Diagnostics Incorporated
  • 16.28. Randox Laboratories Ltd.
  • 16.29. Ri.Mos. Srl
  • 16.30. Siemens Healthineers AG
  • 16.31. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 141. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 142. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 143. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 162. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 163. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 169. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 170. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 171. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)